FOXA1 and prostate adenocarcinoma: In particular, we found none of the ERG-family fusion genes or structural variants, no SPOP mutations, no further FOXA1 mutations, and none of the recurrent whole chromosomal aneuploidies seen in prostate adenocarcinoma (Armenia et al., 2018; Attard et al., 2016; Gasi Tandefelt et al., 2014).